McDermott corporate lawyers advised Israeli pharmaceutical company Galmed Pharmaceuticals on its plans to issue securities raising $150 million for purposes that include R&D, regulatory expenses and acquisition of new technologies.
We use cookies to improve the functionality and performance of this site. By continuing to use this site, you are providing us with your consent to our use of cookies. Please see our Privacy Policy for details.
